Quetiapine in the Treatment of Psychotic Depression - a Pilot Study
This study has been completed.
First Posted: September 12, 2008
Last Update Posted: January 24, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Information provided by (Responsible Party):
PD Dr. Christine Norra, MD, PhD, Ruhr University of Bochum
Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia. Remarkably, preliminary data suggest that the atypical antipsychotic quetiapine has antidepressive properties. Until now, there is limited knowledge concerning the efficacy of quetiapine in major depressive illness and especially in psychotic depression. In our own clinical practice, several patients with psychotic depression were successfully treated with quetiapine as add-on therapy or as monotherapy. On the background of that, the convincing effects of quetiapine in bipolar depression, single-case reports and pilot studies concerning its effectiveness in depressive mood states in psychotic disorders as well as our clinical experiences, it is to assume that a treatment with quetiapine over a 6 weeks period show similar effects in major depressive episode with psychotic features, i.e. psychotic depression. In this pilot study we plan to investigate 20 patients with psychotic features of depression under treatment with quetiapine.
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
||Quetiapine in the Treatment of Psychotic Depression - a Pilot Study
Primary Outcome Measures:
- MADRS [ Time Frame: 6 weeks ]
Secondary Outcome Measures:
- Clinical laboratory evaluation [ Time Frame: 6 weeks ]
- Urinalysis [ Time Frame: 6 weeks ]
- ECG [ Time Frame: 6 weeks ]
- Physical and neurological examination [ Time Frame: 6 weeks ]
- Vital signs [ Time Frame: 6 weeks ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2012 (Final data collection date for primary outcome measure)
Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
Other Name: Seroquel Prolong